Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-020-18468-8 http://scihub22266oqcxt.onion/10.1038/s41467-020-18468-8 32943630!7499171!32943630     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2020 ; 11 (1): 4698 Nephropedia Template TP {{tp|p=32943630|t=2020. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |pdf=|usr=}}{{32943630}} gab.com Text SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=32943630 #FOAvip Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity. Twit Text FOAVip SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=32943630 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32943630 #FOAvip English Wikipedia <ref>{{Cite pmid|32943630}}</ref> SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood #MMPMID32943630 Ng DL; Goldgof GM; Shy BR; Levine AG; Balcerek J; Bapat SP; Prostko J; Rodgers M; Coller K; Pearce S; Franz S; Du L; Stone M; Pillai SK; Sotomayor-Gonzalez A; Servellita V; Martin CSS; Granados A; Glasner DR; Han LM; Truong K; Akagi N; Nguyen DN; Neumann NM; Qazi D; Hsu E; Gu W; Santos YA; Custer B; Green V; Williamson P; Hills NK; Lu CM; Whitman JD; Stramer SL; Wang C; Reyes K; Hakim JMC; Sujishi K; Alazzeh F; Pham L; Thornborrow E; Oon CY; Miller S; Kurtz T; Simmons G; Hackett J Jr; Busch MP; Chiu CY Nat Commun 2020[Sep]; 11 (1): 4698 PMID32943630show ga Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity. |Antibodies, Neutralizing/*blood[MESH] |Antibodies, Viral/immunology[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19[MESH] |COVID-19 Testing[MESH] |Clinical Laboratory Techniques[MESH] |Coronavirus Infections/blood/diagnosis/*epidemiology/immunology[MESH] |Humans[MESH] |Immunoglobulin G/immunology[MESH] |Immunoglobulin M/immunology[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/*epidemiology/immunology[MESH] |SARS-CoV-2[MESH] |San Francisco/epidemiology[MESH] |Sensitivity and Specificity[MESH] |Seroepidemiologic Studies[MESH]SARS-CoV-2 seroprevalence and neutralizing activity in donor and patie(epmc).pdf DeepDyve Pubget Overpricing